Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide

Cheri Enders Klein, Elora Gupta, Joel M Reid, Pamela J. Atherton, Jeff A Sloan, Henry Clement Pitot, Mark J. Ratain, Helen Kastrissios

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Objective: The objective of the study was to develop and validate a population pharmacokinetic model for irinotecan and 2 of its metabolites, SN-38 and SN-38 glucuronide (SN-38G). Methods: Plasma concentrations were obtained during and up to 48 hours after a 90-minute continuous intravenous infusion of irinotecan (100-340 mg/m2) in 78 patients. Data splitting was used to create model-building and model-validation data sets. Pharmacokinetic parameter estimates were obtained by compartmental methods to describe the disposition of metabolites that are dependent on the disposition of the parent compound. Relationships between patient attributes and estimates of clearance (CL) and volume of the central compartment for irinotecan, as well as CL and volume of the central compartment adjusted for the fraction metabolized for SN-38 and SN-38G, were explored by use of generalized additive models and graphic analysis. Selected covariates were introduced into the final population model by stepwise additions or deletions with the likelihood ratio test. Results: SN-38 and SN-38G were shown to be formation rate-limited and were characterized by first-order rate constants of formation and elimination. Two subpopulations of SN-38 disposition were identified, presumably because of differences in the fraction of metabolite formed from the parent compound. Estimated irinotecan CL (25.2 L/h) was similar to that determined in other studies. Age and performance status were found to be important predictors of irinotecan CL, whereas variability in systemic exposure to the active metabolite, SN-38, was predicted by sex and hepatic function. Conclusion: The validated population pharmacokinetic model describing the disposition of irinotecan and 2 of its metabolites should facilitate the design of future studies to elucidate the relative contributions of the parent compound and SN-38 to the pharmacologic and toxic effects of irinotecan therapy.

Original languageEnglish (US)
Pages (from-to)638-647
Number of pages10
JournalClinical Pharmacology and Therapeutics
Volume72
Issue number6
DOIs
StatePublished - Dec 1 2002

Fingerprint

irinotecan
Pharmacokinetics
Population
7-ethyl-10-hydroxycamptothecin glucuronide

ASJC Scopus subject areas

  • Pharmacology

Cite this

Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide. / Klein, Cheri Enders; Gupta, Elora; Reid, Joel M; Atherton, Pamela J.; Sloan, Jeff A; Pitot, Henry Clement; Ratain, Mark J.; Kastrissios, Helen.

In: Clinical Pharmacology and Therapeutics, Vol. 72, No. 6, 01.12.2002, p. 638-647.

Research output: Contribution to journalArticle

Klein, Cheri Enders ; Gupta, Elora ; Reid, Joel M ; Atherton, Pamela J. ; Sloan, Jeff A ; Pitot, Henry Clement ; Ratain, Mark J. ; Kastrissios, Helen. / Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide. In: Clinical Pharmacology and Therapeutics. 2002 ; Vol. 72, No. 6. pp. 638-647.
@article{8454dbe6386143d09c0c9dfb77beeecb,
title = "Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide",
abstract = "Objective: The objective of the study was to develop and validate a population pharmacokinetic model for irinotecan and 2 of its metabolites, SN-38 and SN-38 glucuronide (SN-38G). Methods: Plasma concentrations were obtained during and up to 48 hours after a 90-minute continuous intravenous infusion of irinotecan (100-340 mg/m2) in 78 patients. Data splitting was used to create model-building and model-validation data sets. Pharmacokinetic parameter estimates were obtained by compartmental methods to describe the disposition of metabolites that are dependent on the disposition of the parent compound. Relationships between patient attributes and estimates of clearance (CL) and volume of the central compartment for irinotecan, as well as CL and volume of the central compartment adjusted for the fraction metabolized for SN-38 and SN-38G, were explored by use of generalized additive models and graphic analysis. Selected covariates were introduced into the final population model by stepwise additions or deletions with the likelihood ratio test. Results: SN-38 and SN-38G were shown to be formation rate-limited and were characterized by first-order rate constants of formation and elimination. Two subpopulations of SN-38 disposition were identified, presumably because of differences in the fraction of metabolite formed from the parent compound. Estimated irinotecan CL (25.2 L/h) was similar to that determined in other studies. Age and performance status were found to be important predictors of irinotecan CL, whereas variability in systemic exposure to the active metabolite, SN-38, was predicted by sex and hepatic function. Conclusion: The validated population pharmacokinetic model describing the disposition of irinotecan and 2 of its metabolites should facilitate the design of future studies to elucidate the relative contributions of the parent compound and SN-38 to the pharmacologic and toxic effects of irinotecan therapy.",
author = "Klein, {Cheri Enders} and Elora Gupta and Reid, {Joel M} and Atherton, {Pamela J.} and Sloan, {Jeff A} and Pitot, {Henry Clement} and Ratain, {Mark J.} and Helen Kastrissios",
year = "2002",
month = "12",
day = "1",
doi = "10.1067/mcp.2002.129502",
language = "English (US)",
volume = "72",
pages = "638--647",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide

AU - Klein, Cheri Enders

AU - Gupta, Elora

AU - Reid, Joel M

AU - Atherton, Pamela J.

AU - Sloan, Jeff A

AU - Pitot, Henry Clement

AU - Ratain, Mark J.

AU - Kastrissios, Helen

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Objective: The objective of the study was to develop and validate a population pharmacokinetic model for irinotecan and 2 of its metabolites, SN-38 and SN-38 glucuronide (SN-38G). Methods: Plasma concentrations were obtained during and up to 48 hours after a 90-minute continuous intravenous infusion of irinotecan (100-340 mg/m2) in 78 patients. Data splitting was used to create model-building and model-validation data sets. Pharmacokinetic parameter estimates were obtained by compartmental methods to describe the disposition of metabolites that are dependent on the disposition of the parent compound. Relationships between patient attributes and estimates of clearance (CL) and volume of the central compartment for irinotecan, as well as CL and volume of the central compartment adjusted for the fraction metabolized for SN-38 and SN-38G, were explored by use of generalized additive models and graphic analysis. Selected covariates were introduced into the final population model by stepwise additions or deletions with the likelihood ratio test. Results: SN-38 and SN-38G were shown to be formation rate-limited and were characterized by first-order rate constants of formation and elimination. Two subpopulations of SN-38 disposition were identified, presumably because of differences in the fraction of metabolite formed from the parent compound. Estimated irinotecan CL (25.2 L/h) was similar to that determined in other studies. Age and performance status were found to be important predictors of irinotecan CL, whereas variability in systemic exposure to the active metabolite, SN-38, was predicted by sex and hepatic function. Conclusion: The validated population pharmacokinetic model describing the disposition of irinotecan and 2 of its metabolites should facilitate the design of future studies to elucidate the relative contributions of the parent compound and SN-38 to the pharmacologic and toxic effects of irinotecan therapy.

AB - Objective: The objective of the study was to develop and validate a population pharmacokinetic model for irinotecan and 2 of its metabolites, SN-38 and SN-38 glucuronide (SN-38G). Methods: Plasma concentrations were obtained during and up to 48 hours after a 90-minute continuous intravenous infusion of irinotecan (100-340 mg/m2) in 78 patients. Data splitting was used to create model-building and model-validation data sets. Pharmacokinetic parameter estimates were obtained by compartmental methods to describe the disposition of metabolites that are dependent on the disposition of the parent compound. Relationships between patient attributes and estimates of clearance (CL) and volume of the central compartment for irinotecan, as well as CL and volume of the central compartment adjusted for the fraction metabolized for SN-38 and SN-38G, were explored by use of generalized additive models and graphic analysis. Selected covariates were introduced into the final population model by stepwise additions or deletions with the likelihood ratio test. Results: SN-38 and SN-38G were shown to be formation rate-limited and were characterized by first-order rate constants of formation and elimination. Two subpopulations of SN-38 disposition were identified, presumably because of differences in the fraction of metabolite formed from the parent compound. Estimated irinotecan CL (25.2 L/h) was similar to that determined in other studies. Age and performance status were found to be important predictors of irinotecan CL, whereas variability in systemic exposure to the active metabolite, SN-38, was predicted by sex and hepatic function. Conclusion: The validated population pharmacokinetic model describing the disposition of irinotecan and 2 of its metabolites should facilitate the design of future studies to elucidate the relative contributions of the parent compound and SN-38 to the pharmacologic and toxic effects of irinotecan therapy.

UR - http://www.scopus.com/inward/record.url?scp=0036908854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036908854&partnerID=8YFLogxK

U2 - 10.1067/mcp.2002.129502

DO - 10.1067/mcp.2002.129502

M3 - Article

VL - 72

SP - 638

EP - 647

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 6

ER -